Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307925 | 1.00 | KMT2A (0.67) | KMT2AFPR2ITGB3ITGAVALDH1A1 | |
| SCHEMBL1310417 | 0.92 | KMT2A (0.55) | KMT2AFPR2L3MBTL1 | |
| SCHEMBL1310421 | 0.92 | KMT2A (0.55) | KMT2AFPR2L3MBTL1 | |
| SCHEMBL1310365 | 0.90 | KMT2A (0.57) | KMT2AFPR2ALDH1A1L3MBTL1CA2 | |
| SCHEMBL3689507 | 0.90 | KMT2A (0.57) | KMT2AFPR2ALDH1A1L3MBTL1CA2 | |
| SCHEMBL1310695 | 0.85 | KMT2A (0.49) | KMT2AFPR2ITGB3ALDH1A1CA2 | |
| SCHEMBL1310698 | 0.85 | KMT2A (0.49) | KMT2AFPR2ITGB3ALDH1A1CA2 | |
| SCHEMBL1309687 | 0.85 | KMT2A (0.48) | KMT2AFPR2 | |
| SCHEMBL15016459 | 0.83 | KMT2A (0.47) | KMT2AFPR2ALDH1A1GAA | |
| SCHEMBL15016559 | 0.82 | KMT2A (0.46) | KMT2AFPR2ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-19 | — | — | US | disclosed |
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | disclosed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012131090-A1 | METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-04 | — | — | WO | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052256-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | KMT2A 2301/4885FPR2 213/4885ITGB3 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.